The Carlos Alban Sells 83574 Shares of AbbVie Inc. (ABBV) Stock

Grant Boone
March 25, 2018

Analyst's mean target price for Apple Inc. is $192.54. They expect $1.78 EPS, up 39.06% or $0.50 from last year's $1.28 per share. As a result, the company has Earnings per Share (EPS) growth of 16.61% for the coming year.

Based on a recent bid, this stock (ABBV) was trading at a distance of -3.49% from 20 days simple moving average, and its distance from 50 days simple moving average is 0.08% while it has a distance of 23.80% from the 200 days simple moving average. About 23.01M shares traded or 264.19% up from the average.

On 2/15/2018 AbbVie (NYSE:ABBV) announced a quarterly dividend of $0.96 3.36252189141856% with an ex dividend date of 4/12/2018 which will be payable on 5/15/2018. It has underperformed by 6.07% the S&P500. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. Therefore 45% are positive. Abbvie Inc had 82 analyst reports since July 21, 2015 according to SRatingsIntel. On Wednesday, April 19 the stock rating was maintained by BMO Capital Markets with "Hold". AbbVie now has an average rating of "Buy" and a consensus price target of $120.03. The firm earned "Buy" rating on Monday, February 26 by Jefferies. Leerink Swann downgraded shares of AbbVie from an "outperform" rating to a "market perform" rating and set a $127.00 target price for the company.in a report on Monday, January 29th. BMO Capital Markets maintained AbbVie Inc. (NYSE ABBV) opened at $112.03 on Tuesday. (NYSE:ABBV) has "Buy" rating given on Thursday, September 28 by Piper Jaffray. Shares for $119,351 were sold by Michael Robert A. 70,928 shares were sold by CHASE WILLIAM J, worth $8.31M on Wednesday, February 28. If a buyer buys one share of stock from a seller, then that one share is added to the total volume of that particular stock.

Investors sentiment decreased to 0.85 in Q3 2017.

As of now, Range Resources Corporation has a P/S, P/E and P/B values of 1.53, 0 and 0.64 respectively. It turned negative, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. Following the sale, the executive vice president now owns 133,026 shares in the company, valued at $15,230,146.74. Perigon Wealth Mgmt Ltd Liability Com owns 11,823 shares or 0.34% of their U.S. portfolio. Smith Salley & Assoc holds 2.03% or 116,484 shares in its portfolio. (NYSE:ABBV). Matrix Asset Advsr Inc New York owns 260,917 shares or 3.82% of their United States portfolio. Moreover, Glg Prtnrs LP has 0.02% invested in AbbVie Inc. (NYSE:ABBV) on Monday, October 2 to "Outperform" rating. Bb&T Limited Liability invested in 0.9% or 746,551 shares. 43,990 are owned by Winslow Evans Crocker. AbbVie Inc.'s institutional ownership is 74.1%, while its institutional transactions stand at 0.2%. (NYSE:ABBV). Natl Planning reported 0.93% stake. Amer Assets Investment Mgmt Ltd Llc has invested 0.82% in AbbVie Inc. The company has market cap of $156.53 billion. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. Over the past five trading sessions it is -5.93%; -5.02% for the month; 15.6% for the last quarter; 32.03% for the past six-months; and 71.2% for the last 12 months. Regions holds 1.97% or 2.11M shares in its portfolio. Anthem, Inc. (NYSE:ANTM) has risen 31.86% since March 22, 2017 and is uptrending. The stock's price to sales ratio for trailing twelve months is 6.40 and price to book ratio for the most recent quarter is 35.25, whereas price to cash per share for the most recent quarter are 18.44. AbbVie Inc. maintained activity of relative volume at 4.25. B T Capital Mngmt Dba Alpha Capital Mngmt reported 28,057 shares.

Trump ordered White House officials to sign nondisclosure agreements
The White House is not formally acknowledging the veracity of the presidential guidance first reported by The Washington Post . Asked why Trump was "always so nice to you", Putin said that "this is not about being nice to me personally, in my view".

Ratings analysis reveals 75% of Entegris's analysts are positive.

TRADEMARK VIOLATION WARNING: "Credit Suisse Group Lowers AbbVie (ABBV) Price Target to $98.10" was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. The stock price closed last trading at $98.10. The rating was upgraded by TheStreet to "Buy" on Tuesday, August 11. The stock of Entegris, Inc. The stock has "Buy" rating by Goldman Sachs on Friday, March 10. (NYSE:ABBV) rating on Friday, January 26.

Since January 1, 0001, it had 0 buys, and 8 selling transactions for $9.53 million activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER